nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—ADRA2C—attention deficit hyperactivity disorder	0.529	0.701	CbGaD
Carvedilol—ADRA2A—attention deficit hyperactivity disorder	0.226	0.299	CbGaD
Carvedilol—NPPB—cardiovascular system—attention deficit hyperactivity disorder	0.00337	0.041	CbGeAlD
Carvedilol—HIF1A—forebrain—attention deficit hyperactivity disorder	0.00238	0.029	CbGeAlD
Carvedilol—GJA1—forebrain—attention deficit hyperactivity disorder	0.00231	0.0281	CbGeAlD
Carvedilol—SELE—cardiovascular system—attention deficit hyperactivity disorder	0.00228	0.0277	CbGeAlD
Carvedilol—NPPB—nervous system—attention deficit hyperactivity disorder	0.00216	0.0263	CbGeAlD
Carvedilol—VCAM1—cardiovascular system—attention deficit hyperactivity disorder	0.00209	0.0255	CbGeAlD
Carvedilol—NPPB—central nervous system—attention deficit hyperactivity disorder	0.00208	0.0254	CbGeAlD
Carvedilol—HIF1A—cardiovascular system—attention deficit hyperactivity disorder	0.00201	0.0245	CbGeAlD
Carvedilol—NDUFC2—forebrain—attention deficit hyperactivity disorder	0.00201	0.0245	CbGeAlD
Carvedilol—GJA1—cardiovascular system—attention deficit hyperactivity disorder	0.00195	0.0238	CbGeAlD
Carvedilol—SELE—midbrain—attention deficit hyperactivity disorder	0.00178	0.0216	CbGeAlD
Carvedilol—NDUFC2—cardiovascular system—attention deficit hyperactivity disorder	0.0017	0.0207	CbGeAlD
Carvedilol—NPPB—brain—attention deficit hyperactivity disorder	0.00165	0.0201	CbGeAlD
Carvedilol—VCAM1—midbrain—attention deficit hyperactivity disorder	0.00163	0.0199	CbGeAlD
Carvedilol—HIF1A—midbrain—attention deficit hyperactivity disorder	0.00157	0.0192	CbGeAlD
Carvedilol—GJA1—midbrain—attention deficit hyperactivity disorder	0.00153	0.0186	CbGeAlD
Carvedilol—SELE—nervous system—attention deficit hyperactivity disorder	0.00146	0.0178	CbGeAlD
Carvedilol—SELE—central nervous system—attention deficit hyperactivity disorder	0.00141	0.0171	CbGeAlD
Carvedilol—SELE—cerebellum—attention deficit hyperactivity disorder	0.00137	0.0167	CbGeAlD
Carvedilol—VCAM1—nervous system—attention deficit hyperactivity disorder	0.00134	0.0164	CbGeAlD
Carvedilol—NDUFC2—midbrain—attention deficit hyperactivity disorder	0.00133	0.0162	CbGeAlD
Carvedilol—VCAM1—central nervous system—attention deficit hyperactivity disorder	0.00129	0.0158	CbGeAlD
Carvedilol—HIF1A—nervous system—attention deficit hyperactivity disorder	0.00129	0.0158	CbGeAlD
Carvedilol—Bopindolol—HTR1B—attention deficit hyperactivity disorder	0.00128	0.263	CrCbGaD
Carvedilol—GJA1—nervous system—attention deficit hyperactivity disorder	0.00125	0.0153	CbGeAlD
Carvedilol—HIF1A—central nervous system—attention deficit hyperactivity disorder	0.00124	0.0152	CbGeAlD
Carvedilol—HIF1A—cerebellum—attention deficit hyperactivity disorder	0.00122	0.0148	CbGeAlD
Carvedilol—GJA1—central nervous system—attention deficit hyperactivity disorder	0.00121	0.0147	CbGeAlD
Carvedilol—Tamsulosin—DRD3—attention deficit hyperactivity disorder	0.0012	0.245	CrCbGaD
Carvedilol—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.00119	0.0145	CbGeAlD
Carvedilol—GJA1—cerebellum—attention deficit hyperactivity disorder	0.00118	0.0144	CbGeAlD
Carvedilol—SELE—brain—attention deficit hyperactivity disorder	0.00112	0.0136	CbGeAlD
Carvedilol—NDUFC2—nervous system—attention deficit hyperactivity disorder	0.00109	0.0133	CbGeAlD
Carvedilol—Tamsulosin—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.224	CrCbGaD
Carvedilol—NDUFC2—central nervous system—attention deficit hyperactivity disorder	0.00105	0.0128	CbGeAlD
Carvedilol—NDUFC2—cerebellum—attention deficit hyperactivity disorder	0.00103	0.0125	CbGeAlD
Carvedilol—VCAM1—brain—attention deficit hyperactivity disorder	0.00103	0.0125	CbGeAlD
Carvedilol—HIF1A—brain—attention deficit hyperactivity disorder	0.000988	0.012	CbGeAlD
Carvedilol—GJA1—brain—attention deficit hyperactivity disorder	0.000959	0.0117	CbGeAlD
Carvedilol—VEGFA—cerebellum—attention deficit hyperactivity disorder	0.000932	0.0114	CbGeAlD
Carvedilol—ADRB1—forebrain—attention deficit hyperactivity disorder	0.000866	0.0105	CbGeAlD
Carvedilol—NDUFC2—brain—attention deficit hyperactivity disorder	0.000835	0.0102	CbGeAlD
Carvedilol—Tamsulosin—DRD2—attention deficit hyperactivity disorder	0.000827	0.17	CrCbGaD
Carvedilol—VEGFA—brain—attention deficit hyperactivity disorder	0.000757	0.00922	CbGeAlD
Carvedilol—ADRB1—cardiovascular system—attention deficit hyperactivity disorder	0.000732	0.00892	CbGeAlD
Carvedilol—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000685	0.00834	CbGeAlD
Carvedilol—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000662	0.00806	CbGeAlD
Carvedilol—KCNH2—forebrain—attention deficit hyperactivity disorder	0.000661	0.00805	CbGeAlD
Carvedilol—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.000647	0.00788	CbGeAlD
Carvedilol—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000637	0.00776	CbGeAlD
Carvedilol—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.000623	0.00759	CbGeAlD
Carvedilol—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000579	0.00705	CbGeAlD
Carvedilol—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000559	0.00681	CbGeAlD
Carvedilol—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000521	0.00634	CbGeAlD
Carvedilol—ADRA1B—brain—attention deficit hyperactivity disorder	0.000506	0.00616	CbGeAlD
Carvedilol—ADRA1D—brain—attention deficit hyperactivity disorder	0.000495	0.00602	CbGeAlD
Carvedilol—PTGS1—forebrain—attention deficit hyperactivity disorder	0.000491	0.00598	CbGeAlD
Carvedilol—Propranolol—HTR1B—attention deficit hyperactivity disorder	0.00048	0.0985	CrCbGaD
Carvedilol—ADRB1—nervous system—attention deficit hyperactivity disorder	0.00047	0.00573	CbGeAlD
Carvedilol—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.000454	0.00553	CbGeAlD
Carvedilol—ADRB1—central nervous system—attention deficit hyperactivity disorder	0.000453	0.00551	CbGeAlD
Carvedilol—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000437	0.00532	CbGeAlD
Carvedilol—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000431	0.00525	CbGeAlD
Carvedilol—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000431	0.00525	CbGeAlD
Carvedilol—PTGS1—cardiovascular system—attention deficit hyperactivity disorder	0.000415	0.00505	CbGeAlD
Carvedilol—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000403	0.00491	CbGeAlD
Carvedilol—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000372	0.00453	CbGeAlD
Carvedilol—ADRB1—brain—attention deficit hyperactivity disorder	0.000359	0.00438	CbGeAlD
Carvedilol—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000359	0.00437	CbGeAlD
Carvedilol—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000358	0.00436	CbGeAlD
Carvedilol—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000354	0.00431	CbGeAlD
Carvedilol—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.00035	0.00426	CbGeAlD
Carvedilol—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000346	0.00421	CbGeAlD
Carvedilol—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000344	0.00419	CbGeAlD
Carvedilol—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000341	0.00415	CbGeAlD
Carvedilol—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000338	0.00411	CbGeAlD
Carvedilol—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000333	0.00406	CbGeAlD
Carvedilol—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.000303	0.00369	CbGeAlD
Carvedilol—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.000292	0.00356	CbGeAlD
Carvedilol—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00029	0.00353	CbGeAlD
Carvedilol—ADRA1A—brain—attention deficit hyperactivity disorder	0.000284	0.00346	CbGeAlD
Carvedilol—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000283	0.00344	CbGeAlD
Carvedilol—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000276	0.00337	CbGeAlD
Carvedilol—KCNH2—brain—attention deficit hyperactivity disorder	0.000274	0.00334	CbGeAlD
Carvedilol—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000272	0.00331	CbGeAlD
Carvedilol—ADRA2C—brain—attention deficit hyperactivity disorder	0.000271	0.0033	CbGeAlD
Carvedilol—PTGS1—nervous system—attention deficit hyperactivity disorder	0.000266	0.00324	CbGeAlD
Carvedilol—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000266	0.00324	CbGeAlD
Carvedilol—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000266	0.00324	CbGeAlD
Carvedilol—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.00026	0.00317	CbGeAlD
Carvedilol—PTGS1—central nervous system—attention deficit hyperactivity disorder	0.000256	0.00312	CbGeAlD
Carvedilol—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000245	0.00299	CbGeAlD
Carvedilol—CYP1A1—brain—attention deficit hyperactivity disorder	0.000232	0.00282	CbGeAlD
Carvedilol—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000222	0.00271	CbGeAlD
Carvedilol—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000219	0.00267	CbGeAlD
Carvedilol—ADRA2A—brain—attention deficit hyperactivity disorder	0.000216	0.00263	CbGeAlD
Carvedilol—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000214	0.00261	CbGeAlD
Carvedilol—CYP2E1—brain—attention deficit hyperactivity disorder	0.000211	0.00257	CbGeAlD
Carvedilol—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000211	0.00257	CbGeAlD
Carvedilol—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000206	0.00251	CbGeAlD
Carvedilol—PTGS1—brain—attention deficit hyperactivity disorder	0.000204	0.00248	CbGeAlD
Carvedilol—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000192	0.00233	CbGeAlD
Carvedilol—CYP2D6—brain—attention deficit hyperactivity disorder	0.000167	0.00204	CbGeAlD
Carvedilol—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000157	0.00192	CbGeAlD
Carvedilol—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000152	0.00185	CbGeAlD
Carvedilol—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000148	0.0018	CbGeAlD
Carvedilol—ABCB1—brain—attention deficit hyperactivity disorder	0.00012	0.00147	CbGeAlD
Carvedilol—ADRB3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.01e-05	0.000127	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.01e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.99e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	1.99e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.98e-05	0.000124	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.96e-05	0.000123	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	1.93e-05	0.000122	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.93e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.92e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.92e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	1.91e-05	0.00012	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.9e-05	0.00012	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.9e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.89e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.89e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.88e-05	0.000119	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.87e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.87e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.87e-05	0.000118	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.87e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.87e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.86e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.86e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.85e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.84e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.84e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.82e-05	0.000115	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.82e-05	0.000115	CbGpPWpGaD
Carvedilol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	1.81e-05	0.000114	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.8e-05	0.000113	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.79e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.79e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.78e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	1.76e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.76e-05	0.000111	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.75e-05	0.00011	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.75e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.74e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.74e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.74e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.73e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	1.73e-05	0.000109	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.73e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.72e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.72e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.71e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.69e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.68e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.68e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.67e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.66e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.66e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.64e-05	0.000103	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.62e-05	0.000102	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.61e-05	0.000101	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.61e-05	0.000101	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.6e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.59e-05	0.0001	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.57e-05	9.85e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.56e-05	9.84e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.56e-05	9.81e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.55e-05	9.75e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.53e-05	9.62e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.52e-05	9.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.52e-05	9.56e-05	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	1.5e-05	9.46e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.5e-05	9.44e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.45e-05	9.14e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.45e-05	9.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.45e-05	9.1e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.44e-05	9.06e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.43e-05	9.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	1.43e-05	8.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.43e-05	8.99e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.42e-05	8.96e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.42e-05	8.94e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.42e-05	8.91e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.41e-05	8.85e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	1.4e-05	8.84e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.4e-05	8.83e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.39e-05	8.77e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	1.38e-05	8.68e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.37e-05	8.6e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.35e-05	8.52e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.35e-05	8.5e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.35e-05	8.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.34e-05	8.46e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.34e-05	8.42e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.34e-05	8.41e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.34e-05	8.41e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.34e-05	8.41e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.33e-05	8.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.32e-05	8.33e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.32e-05	8.3e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.31e-05	8.26e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.31e-05	8.25e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.31e-05	8.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.31e-05	8.25e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.31e-05	8.24e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.31e-05	8.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.31e-05	8.22e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.29e-05	8.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.29e-05	8.12e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.27e-05	7.99e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.26e-05	7.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.26e-05	7.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.26e-05	7.92e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.24e-05	7.83e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.24e-05	7.82e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.24e-05	7.78e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.24e-05	7.78e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.23e-05	7.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.22e-05	7.68e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.22e-05	7.68e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.22e-05	7.67e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.22e-05	7.66e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.21e-05	7.61e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	1.21e-05	7.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.2e-05	7.57e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.2e-05	7.56e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.2e-05	7.55e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.2e-05	7.54e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.19e-05	7.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.18e-05	7.45e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.18e-05	7.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.18e-05	7.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.17e-05	7.4e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.17e-05	7.39e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.17e-05	7.35e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.16e-05	7.28e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.14e-05	7.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.14e-05	7.19e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.14e-05	7.16e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.13e-05	7.12e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	1.13e-05	7.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.12e-05	7.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.12e-05	7.04e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.11e-05	7e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.11e-05	6.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.1e-05	6.96e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.1e-05	6.94e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.1e-05	6.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.09e-05	6.87e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.09e-05	6.85e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.09e-05	6.85e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.07e-05	6.72e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	1.07e-05	6.7e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—COMT—attention deficit hyperactivity disorder	1.06e-05	6.69e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	1.06e-05	6.66e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.06e-05	6.64e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.05e-05	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.03e-05	6.48e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.03e-05	6.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.03e-05	6.46e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.02e-05	6.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.01e-05	6.38e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.98e-06	6.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.95e-06	6.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.91e-06	6.24e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.88e-06	6.22e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.87e-06	6.22e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	9.87e-06	6.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.78e-06	6.16e-05	CbGpPWpGaD
Carvedilol—XDH—Metabolism—EP300—attention deficit hyperactivity disorder	9.74e-06	6.13e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	9.72e-06	6.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.66e-06	6.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.55e-06	6.01e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.41e-06	5.92e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	9.31e-06	5.86e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.31e-06	5.86e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.25e-06	5.82e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	9.23e-06	5.81e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.23e-06	5.81e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	9.15e-06	5.76e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	9.15e-06	5.76e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	9.08e-06	5.71e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.03e-06	5.69e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9e-06	5.66e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.98e-06	5.65e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.81e-06	5.55e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	8.65e-06	5.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	8.59e-06	5.41e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.55e-06	5.38e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.51e-06	5.36e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.44e-06	5.31e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.36e-06	5.26e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	7.94e-06	5e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.89e-06	4.97e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.89e-06	4.97e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	7.88e-06	4.96e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.88e-06	4.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.79e-06	4.9e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	7.76e-06	4.88e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.72e-06	4.86e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.62e-06	4.8e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.52e-06	4.73e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	7.49e-06	4.71e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.44e-06	4.68e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.44e-06	4.68e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.37e-06	4.64e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.21e-06	4.54e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.21e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.21e-06	4.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.1e-06	4.47e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.08e-06	4.46e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.02e-06	4.42e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.95e-06	4.38e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.94e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.3e-06	3.97e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.3e-06	3.97e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	6.08e-06	3.83e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.08e-06	3.83e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6e-06	3.78e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	5.99e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	5.98e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	5.94e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.86e-06	3.69e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	5.64e-06	3.55e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	5.6e-06	3.52e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	5.59e-06	3.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.56e-06	3.5e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	5.55e-06	3.49e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	5.38e-06	3.39e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.86e-06	3.06e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	4.78e-06	3.01e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	4.74e-06	2.99e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.63e-06	2.91e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.6e-06	2.89e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	4.57e-06	2.88e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—EP300—attention deficit hyperactivity disorder	4.56e-06	2.87e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.53e-06	2.85e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.13e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.09e-06	2.57e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.04e-06	2.54e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.82e-06	2.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.76e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	3.71e-06	2.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	3.69e-06	2.32e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	3.66e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	3.41e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.34e-06	2.1e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	3.21e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.1e-06	1.95e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	2.57e-06	1.61e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.42e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	2.4e-06	1.51e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	2.05e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.58e-06	9.95e-06	CbGpPWpGaD
